Fu Binjie, Hu Liangbo, Lv Fajin, Huang Junhao, Li Wangjia, Ouyang Yu, Chu Zhigang
Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Department of Radiology, Yongchuan Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Infect Drug Resist. 2020 Aug 3;13:2681-2687. doi: 10.2147/IDR.S258677. eCollection 2020.
To determine whether new pulmonary lesions will develop in COVID-19 patients with negative initial chest CT findings and to investigate their CT features and outcome during treatment.
Data were collected retrospectively from 29 patients who had tested positive for COVID-19 by reverse-transcription polymerase chain reaction testing but negative by initial chest CT from January 22 to February 17, 2020. Clinical manifestations, laboratory indicators, and follow-up CT data were evaluated.
Among 317 confirmed COVID-19 patients, 29 (9.1%) (mean ± SD, 38.5 ± 20.5 years; 12 women) with negative initial chest CT findings were evaluated. New pulmonary lesions developed in 10 (34.5%) patients on follow-up CT. Mean time from onset of new lesions to initial CT was 5.8 ± 3.0 days (range: 2-12 days). New lesions (mean involved lobes and segments: 2.5 ± 1.6 [range: 1-5] and 4.5 ± 4.5 [range: 1-13]) were mainly spherical/patchy ground-glass opacities frequently located in the left lower lobe (9, 90.0%). Among the 10 patients, lesions in 6 (60.0%) indicated progression after occurrence, and those in 10 (100.0%) indicated significant absorption on latest CT. When new lesions developed, 6 (60.0%) patients developed new symptoms or had aggravated symptoms and 3 (30.0%) had decreased lymphocyte count. Patients with worsening symptoms had higher involvement of lung segments (mean: 6.5 ± 5.0, range: 1-13) than asymptomatic patients (mean: 1.5 ± 0.6, range: 1-2) (P = 0.057).
In COVID-19 patients with negative initial chest CT findings, new pulmonary lesions may develop during treatment. Repeat CT is necessary for monitoring the disease, especially when patients have worsening symptoms or laboratory indicators.
确定初始胸部CT检查结果为阴性的新型冠状病毒肺炎(COVID-19)患者是否会出现新的肺部病变,并研究其治疗期间的CT特征及转归。
回顾性收集2020年1月22日至2月17日期间29例经逆转录聚合酶链反应检测确诊为COVID-19但初始胸部CT检查结果为阴性的患者的数据。对临床表现、实验室指标及随访CT数据进行评估。
在317例确诊的COVID-19患者中,对29例(9.1%)(平均±标准差,38.5±20.5岁;12例女性)初始胸部CT检查结果为阴性的患者进行了评估。随访CT检查发现10例(34.5%)患者出现了新的肺部病变。新病变出现至初始CT检查的平均时间为5.8±3.0天(范围:2 - 12天)。新病变(平均累及肺叶和肺段数:2.5±1.6[范围:1 - 5]和4.5±4.5[范围:1 - 13])主要为球形/斑片状磨玻璃影,常见于左肺下叶(9例,90.0%)。10例患者中,6例(60.0%)病变出现后呈进展性,10例(100.0%)在最新CT检查时显示明显吸收。新病变出现时,6例(60.0%)患者出现新症状或症状加重,3例(30.0%)淋巴细胞计数下降。症状加重的患者肺段受累程度(平均:6.5±5.0,范围:1 - 13)高于无症状患者(平均:1.5±0.6,范围:1 - 2)(P = 0.057)。
初始胸部CT检查结果为阴性的COVID-19患者在治疗期间可能会出现新的肺部病变。重复CT检查对于监测病情很有必要,尤其是当患者症状加重或实验室指标异常时。